They aren't just "pandemic stocks." ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Pfizer has reached a turning point.

If you are wondering whether Pfizer's current share price reflects its long term potential or lingering concerns, looking closely at what you are paying for each dollar of its business is a useful ...

March 17 () - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression ‌or death by 40% in ...

Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.

(Reuters) -Pfizer said on Thursday it completed an acquisition worth up to $10 billion of biotech firm Metsera after winning shareholder approval, securing a path into the fast-growing obesity ...

About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Pfizer (PFE) is back in focus after recent trading left the shares around $27.32, prompting investors to reassess the company’s value score of 3, revenue of $62.6b, and net income of $7.7b. See our ...